We are live on ! Find out more
SMMT icon

Summit Therapeutics
SMMT

11 hedge funds and large institutions have $29.6M invested in Summit Therapeutics in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

38% more funds holding

Funds holding: 8 → 11 (+3)

11% less capital invested

Capital invested by funds: $33.2M → $29.6M (-$3.57M)

Holders
11
Holders Change
+3
Holders Change %
+37.5%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
+$1.13M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$777K
3
AIC
AWM Investment Company
New York
+$484K
4
SFM
Sphera Funds Management
Israel
+$342K
5
GPCM
Granite Point Capital Management
Massachusetts
+$35.8K

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
-$1.72M

SMMT Hedge Fund Activity: Q2 2015 in Review

11 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2015, worth a combined $29.6M — down 11% from $33.2M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SMMT positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $1.13M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $1.72M sold.

  • 11 institutional investors held Summit Therapeutics (SMMT) as of Q2 2015, up from 8 in Q1 2015.
  • Funds reported $29.6M of Summit Therapeutics stock for Q2 2015, down 11% quarter-over-quarter.
  • 5 funds opened new Summit Therapeutics positions in Q2 2015 and 2 closed out, a net change of +3 holders.
  • The largest Summit Therapeutics buyer in Q2 2015 was EverPoint Asset Management, an estimated $1.13M added.
  • The largest Summit Therapeutics seller in Q2 2015 was Janus Henderson Group, an estimated $1.72M sold.

Based on aggregated 13F filings for Q2 2015.